Clinical trial
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
NCT00003129 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003129 |
|---|---|
| Title | Chemotherapy in Treating Patients With Early-Stage Bladder Cancer |
| Official title | Phase II Study of Intravesical Therapy With AD 32 in Patients With Papillary Urothelial Carcinoma or Carcinoma in Situ (CIS) Refractory to Prior Therapy With Bacillus Calmette-Guerin |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | valrubicin |
| Enrollment | 75 |
| Start date | Sep 1, 1998 |
| Primary completion | Nov 1, 2002 |
| Completion | May 1, 2009 |
| First posted | Apr 18, 2003 |
| Last update posted | Jun 22, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: